ADMA Biologics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ADMA

The DJS Law Group reminds investors of a class action lawsuit against ADMA Biologics, Inc. ("ADMA" or "the Company") (NASDAQ: ADMA ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of ADMA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery. CLASS PERIOD: August 9, 2024 to March 25, 2026 DEADLINE: August 10, 2026 CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. ADMA failed to disclose a related party transaction. The Company stuffed the channel to simulate sales activity. Based on these facts, ADMA's public statements were false and materially misleading throughout the class period. If you are a shareholder who suffered a loss, contact us to participate.